【佳學(xué)基因檢測(cè)】ADRB2基因檢測(cè)的意義

基因檢測(cè)的序列名稱(chēng)：

ADRB2

人體基因序列變化與疾病表征數(shù)據(jù)庫(kù)中的基因代碼：

154

人體基因序列數(shù)據(jù)庫(kù)中國(guó)際交流名稱(chēng)全稱(chēng)

adrenoceptor beta 2

中國(guó)數(shù)據(jù)庫(kù)中基因全稱(chēng)：腎上腺素受體2基因檢測(cè)報(bào)告英文版基因簡(jiǎn)介

This gene encodes beta-2-adrenergic receptor which is a member of the G protein-coupled receptor superfamily. This receptor is directly associated with one of its ultimate effectors, the class C L-type calcium channel Ca(V)1.2. This receptor-channel complex also contains a G protein, an adenylyl cyclase, cAMP-dependent kinase, and the counterbalancing phosphatase, PP2A. The assembly of the signaling complex provides a mechanism that ensures specific and rapid signaling by this G protein-coupled receptor. This gene is intronless. Different polymorphic forms, point mutations, and/or downregulation of this gene are associated with nocturnal asthma, obesity and type 2 diabetes. [provided by RefSeq, Jul 2008]

基因突變所影響的基因信息

該基因編碼β-2-腎上腺素能受體，該受體是G蛋白偶聯(lián)受體超家族的成員。該受體與其賊終效應(yīng)物之一C類(lèi)L型鈣通道Ca（V）1.2直接相關(guān)。該受體通道復(fù)合物還包含一個(gè)G蛋白，一個(gè)腺苷酸環(huán)化酶，cAMP依賴(lài)性激酶和一個(gè)平衡磷酸酶PP2A。信號(hào)傳導(dǎo)復(fù)合物的組裝提供了一種機(jī)制，可確保通過(guò)這種G蛋白偶聯(lián)受體實(shí)現(xiàn)特異性和快速的信號(hào)傳導(dǎo)。該基因是無(wú)內(nèi)含子的。該基因的不同多態(tài)形式，點(diǎn)突變和/或下調(diào)與夜間哮喘，肥胖癥和2型糖尿病有關(guān)。[由RefSeq提供，2008年7月]

國(guó)際國(guó)內(nèi)該堿基因序列的其他英語(yǔ)文字母簡(jiǎn)稱(chēng)：

ADRB2R, ADRBR, B2AR, BAR, BETA2AR

基因解碼對(duì)該基因序列在細(xì)胞核中的染色體所給予的編號(hào)：

該基因序列位于人類(lèi)第5號(hào)染色體上。

基因解碼對(duì)基因序列的正確定位

該基因序列在GRCh37版本中的起始位置坐標(biāo)為：148206156；結(jié)束位置坐標(biāo)為：148254628。該基因序列在GRCh38版本中的起始位置坐標(biāo)為：148826593；結(jié)束位置坐標(biāo)為：148828634。正確的基因信息定位是基因檢測(cè)和對(duì)檢測(cè)結(jié)果進(jìn)行正確解讀的關(guān)鍵。

佳學(xué)基因解碼對(duì)該基因的功能分類(lèi)：國(guó)際版

G-protein coupled receptors/GPCRs excl olfactory receptors;Transporters

基因解碼對(duì)該基因的功能分類(lèi)：中文版

G 蛋白偶聯(lián)受體/GPCR，不包括嗅覺(jué)受體；轉(zhuǎn)運(yùn)蛋白

結(jié)構(gòu)與功能基因解碼所揭示的該基因在細(xì)胞內(nèi)發(fā)揮作用的場(chǎng)所（國(guó)際版）：

Cytosol(Uncertain)

結(jié)構(gòu)與功能基因解碼所揭示的該基因發(fā)揮作用的細(xì)胞內(nèi)位置（中文版）：

胞質(zhì)溶膠

該基因序列變化后增加的疾病風(fēng)險(xiǎn)（國(guó)際版）：

Ventricular Dysfunction, Left; Hypokalemia; Hyperlipidemia; Fibrosis; Lung diseases; nervous system disorder; Insulin Resistance; Cardiomyopathy, Dilated; Asthma; Cardiomyopathies; Tremor; Myocardial Ischemia; Obesity; Autistic Disorder; Stomach Neoplasms; Prostatic Neoplasms; Bipolar Disorder

如果該基因突變后，風(fēng)險(xiǎn)可能增加的疾病類(lèi)型（中文版）：

心室功能障礙左；低鉀血癥；高脂血癥；纖維化；肺部疾病；神經(jīng)系統(tǒng)紊亂；胰島素抵抗;心肌病擴(kuò)張型；哮喘;心肌病;震顫;心肌缺血；肥胖;自閉癥；胃腫瘤；前列腺腫瘤；躁郁癥

GWAS基因檢測(cè)所建立的與該基因的疾病關(guān)聯(lián)（國(guó)際版）：

正在通過(guò)基因解碼技術(shù)進(jìn)行收集、查證并編輯，請(qǐng)關(guān)注佳學(xué)基因，獲得及明更新的人類(lèi)基因序列變化與疾病表征數(shù)據(jù)庫(kù)的更新內(nèi)容

GWAS基因檢測(cè)所解碼的該基因突變會(huì)增加風(fēng)險(xiǎn)的疾病種類(lèi)（中文版）：

正在通過(guò)基因解碼技術(shù)進(jìn)行收集、查證并編輯，請(qǐng)關(guān)注佳學(xué)基因，獲得及明更新的人類(lèi)基因序列變化與疾病表征數(shù)據(jù)庫(kù)的更新內(nèi)容

以該基因做靶點(diǎn)的藥物（國(guó)際版）：

Betaxolol (Protein homodimerization activity);Isoetarine (Protein homodimerization activity);Cabergoline (Protein homodimerization activity);Metoprolol (Protein homodimerization activity);Atenolol (Protein homodimerization activity);Norepinephrine (Protein homodimerization activity);Mirtazapine (Protein homodimerization activity);Timolol (Protein homodimerization activity);Phenylpropanolamine (Protein homodimerization activity);Dipivefrin (Protein homodimerization activity);Sotalol (Protein homodimerization activity);Carteolol (Protein homodimerization activity);Propranolol (Protein homodimerization activity);Labetalol (Protein homodimerization activity);Bisoprolol (Protein homodimerization activity);Epinephrine (Protein homodimerization activity);Orciprenaline (Protein homodimerization activity);Dobutamine (Protein homodimerization activity);Pseudoephedrine (Protein homodimerization activity);Alprenolol (Protein homodimerization activity);Ritodrine (Protein homodimerization activity);Terbutaline (Protein homodimerization activity);Bitolterol (Protein homodimerization activity);Phenoxybenzamine (Protein homodimerization activity);Salmeterol (Protein homodimerization activity);Pindolol (Protein homodimerization activity);Formoterol (Protein homodimerization activity);Salbutamol (Protein homodimerization activity);Isoprenaline (Protein homodimerization activity);Arbutamine (Protein homodimerization activity);Carvedilol (Protein homodimerization activity);Desipramine (Protein homodimerization activity);Acebutolol (Protein homodimerization activity);Nadolol (Protein homodimerization activity);Levobunolol (Protein homodimerization activity);Metipranolol (Protein homodimerization activity);Arformoterol (Protein homodimerization activity);Fenoterol (Protein homodimerization activity);Pirbuterol (Protein homodimerization activity);Bevantolol (Protein homodimerization activity);Penbutolol (Protein homodimerization activity);Ephedra (Protein homodimerization activity);Procaterol (Protein homodimerization activity);Clenbuterol (Protein homodimerization activity);Bambuterol (Protein homodimerization activity);Oxprenolol (Protein homodimerization activity);Celiprolol (Protein homodimerization activity);Nebivolol (Protein homodimerization activity);Indacaterol (Protein homodimerization activity);NCX 950 (Protein homodimerization activity);Asenapine (Protein homodimerization activity);Droxidopa (Protein homodimerization activity);(2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol (Protein homodimerization activity);Bopindolol (Protein homodimerization activity);Bupranolol (Protein homodimerization activity);Olodaterol (Protein homodimerization activity);Vilanterol (Protein homodimerization activity)

針對(duì)該基因所產(chǎn)生的突變，可能有正確效果的藥物（中文版）：

倍他洛爾（蛋白質(zhì)同二聚化活性）；異丙酮酸（蛋白質(zhì)同二聚化活性）；卡麥角林（蛋白質(zhì)同二聚化活性）；美托洛爾（蛋白質(zhì)同二聚化活性）；阿替洛爾（蛋白質(zhì)同二聚化活性）；去甲腎上腺素（蛋白質(zhì)同二聚化活性）；米氮平（蛋白質(zhì)同二聚化活性）；噻嗎洛爾(蛋白質(zhì)同二聚化活性);苯丙醇胺(蛋白質(zhì)同二聚化活性);地匹夫林(蛋白質(zhì)同二聚化活性);索他洛爾(蛋白質(zhì)同二聚化活性);卡替洛爾(蛋白質(zhì)同二聚化活性);普萘洛爾(蛋白質(zhì)同二聚化活性);拉貝洛爾(蛋白質(zhì)同二聚化活性);比索洛爾( Protein homodimerization activity);腎上腺素(Protein homodimerization activity);Orciprenaline(Protein homodimerization activity);多巴酚丁胺(Dobutamine)(Protein homodimerization activity);Pseudoephedrine(Protein homodimerization activity);Alprenolol(Protein homodimerization activity);利托君(Protein homodimerization activity);特布他林(Protein homodimerization activity)同二聚活性);比托特羅(蛋白質(zhì)同二聚活性);苯氧芐明(蛋白質(zhì)同二聚活性);沙美特羅(蛋白質(zhì)同二聚活性);吲哚洛爾(蛋白質(zhì)同二聚活性);福莫特羅(蛋白質(zhì)同二聚活性);沙丁胺醇(蛋白質(zhì)同二聚活性);異丙腎上腺素(蛋白質(zhì)同二聚活性)活性);熊果胺(蛋白質(zhì)同二聚活性);卡維地洛(蛋白質(zhì)同二聚活性);地昔帕明(蛋白質(zhì)同二聚活性);醋丁洛爾(蛋白質(zhì)同二聚活性);納多洛爾(蛋白質(zhì)同二聚活性);左布洛爾(蛋白質(zhì)同二聚活性);美替洛爾(蛋白質(zhì)同二聚活性) );阿福特羅(蛋白質(zhì)同二聚活性);非諾特羅(蛋白質(zhì)同二聚活性);吡布特羅(蛋白質(zhì)同二聚活性);貝伐洛爾(蛋白質(zhì)同二聚活性);噴布洛爾(蛋白質(zhì)同二聚活性);麻黃(蛋白質(zhì)同二聚活性);丙卡特羅(蛋白質(zhì)同二聚活性) ;瘦肉精（蛋白質(zhì)同二聚化活性）；班布特羅（蛋白質(zhì)同二聚化活性）；氧烯洛爾（蛋白質(zhì)同二聚化活性）；賽力洛爾（蛋白質(zhì)同二聚化活性）；奈必洛爾（蛋白質(zhì)同二聚化活性）；茚達(dá)特羅（蛋白質(zhì)同二聚化活性）；NCX 950（蛋白質(zhì)同二聚化活性） ;Asenapine（蛋白質(zhì)同二聚化活性）；屈昔多巴（蛋白質(zhì)同二聚化活性）；(2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol（蛋白質(zhì)同二聚化活性）；Bopindolol（蛋白質(zhì)同二聚化活性）同二聚化活性);丁萘洛爾(蛋白質(zhì)同二聚化活性);奧達(dá)特羅(蛋白質(zhì)同二聚化活性);維蘭特羅(蛋白質(zhì)同二聚化活性)

(責(zé)任編輯：佳學(xué)基因)